ArticleScientific reports2021

A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer's disease and tauopathy in mice.

Tomohiro Onishi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.